← Back to Blog
AI News

AI-Powered Drug Discovery Platform Launched as Neuralink Advances Thought Control

AI Drug Discovery dd4gh Medicines for Malaria Venture deepmirror Neuralink Brain Chips Thought Control SheSparks 2026 Global Capability Centers GCC Palantir Robotics Summit

Medicines for Malaria Venture and deepmirror launched Drug Design for Global Health (dd4gh), an open-access AI platform to accelerate drug discovery for diseases affecting low

  • and middle-income countries, with partial funding from the Bill & Melinda Gates Foundation, according to a press release. The AI models are trained on datasets from studies in malaria, tuberculosis, and neglected tropical diseases (NTDs), and is free to eligible researchers working on diseases that primarily affect LMIC populations.

Neuralink's brain chips are advancing brain-computer interface technology, enabling thought control and digital communication, according to Cybernews.

At SheSparks 2026 on March 14, a session titled ‘Women Architects of Enterprise AI in the GCC Era’ discussed how women leaders are shaping AI adoption and championing responsible innovation in Global Capability Centers (GCCs), reports YourStory.

An AI software stock could outperform Palantir over the next year, according to a report by The Motley Fool.

The Robotics Summit featured a keynote on building reliable robots at scale for commercial fleets, according to The Robot Report.

Modern businesses must embrace innovation to thrive in today’s tech-savvy marketplace shaped by rapid technological change and evolving consumer expectations, reports TechBullion.

Sources:

Share this post:

Twitter LinkedIn